Comment: Serotonin Syndrome,Mydriasis,and Cyproheptadine

Abstract

Get full access to this article

View all access options for this article.

References

McDaniel

. Serotonin syndrome: Early management with cyproheptadine. Ann Pharmacother 2001; 35: 870–3.

Lane

Baldwin

. Selective serotonin reuptake inhibitor—induced serotonin syndrome: Review. J Clin Psychopharmacol 1997; 17: 208–21.

Whyte

. Serotonin syndrome complicating treatment of recurrent depression. Curr Ther 1999; 40: 6–7.

Gillman

. The serotonin syndrome and its treatment. J Psychopharmacol 1999; 13: 100–9.

Isbister

Dawson

Whyte

. Serotonin syndrome and 5-HT_2A antagonism. Ann Pharmacother 2001; 35.

Sternbach

. The serotonin syndrome. Am J Psychiatry 1991; 148: 705–13.

Hegerl

Bottlender

Gallinat

Kuss

Ackenheil

Moller

. The serotonin syndrome scale: First results on validity. Eur Arch Psychiatry Clin Neurosci 1998; 248: 96–103.

Nisijima

Yoshino

Yui

Katoh

. Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res 2001; 890: 23–31.

Borsini

Brambilla

Cesana

Grippa

. Lack of interaction between flibanserin and antidepressants in inducing serotonergic syndrome in rats. Int J Neuropsychopharmacol 2001; 4: 9–15.

10.

Chan

Graudins

Whyte

Dawson

Braitberg

Duggin

. Serotonin syndrome resulting from drug interactions. Med J Aust 1998; 169: 523–5.

11.

Prior

Isbister

Dawson

Whyte

. Serotonin toxicity with therapeutic doses of dexamphetamine and venlafaxine. Med J Aust 2001; 175:(in press).